Медицинская литература. Новинки

 

 

 

 

 

 

Дифференциальная диагностика инциденталом надпочечников

Вы можете загрузить полный текст статьи в формате pdf

Ключевые слова:

Литература:
1. Young W.F. Jr. Management approaches to adrenal incidentalomas: a view from Rochester, Minnesota. Endocr. Metab.
Clin. N. Am. 2000; 29:159–185.
2. Bovio S., Cataldi A., Reimondo G. et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J. Endocr. Invest. 2006; 29: 298–302.
3. Mansmann G., Lau J., Balk E. et al. The clinically inapparent
adrenal mass: update in diagnosis and management. Endocr.
Rev. 2004; 25:309–340.
4. Terzolo M., Pia A., Ali A. et al. Adrenal incidentaloma: a new
cause of the metabolic syndrome? J. Clin. Endocr. Metab.
2002; 87: 998–1003.
5. Korobkin M., Brodeur F.J., Francis I.R. et al. CT timeattenuation washout curves of adrenal adenomas and nonadenomas.
Am. J. Roentgenol. 1998; 170: 747–752.
6. Pena C.S., Boland G.W., Hahn P.F. et al. Characterization of
indeterminate (lipid-poor) adrenal masses: use of washout
characteristics at contrastenhanced CT. Radiology 2000;
217: 798–802.
7. Young W.F.Jr. The Incidentally Discovered Adrenal Mass.
N. Engl. J. Med. 2007; 356: 601–610.
8. Barzon L., Sonino N., Fallo F. et al. Prevalence and natural
history of adrenal incidentalomas. Eur. J. Endocr. 2003; 149:
273–285.
9. Cawood T.J., Hunt P.J., O’Shea D. et al. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the
risk of the adrenal lesion becoming malignant; time for a
rethink? Literature review. Eur. J. Endocr. 2009; 161: 513–527.
10. Etxabe J., Vazquez J.A. Morbidity and mortality in Cushing’s
disease: an epidemiological approach. Clin. Endocr. (Oxf.)
1994; 40: 479–484.
11. Lindholm J., Juul S., Jorgensen J.O. et al. Incidence and late
prognosis of Cushing’s syndrome: a population-based study.
J. Clin. Endocr. Metab. 2001; 86: 117–123.
12. Pecori G.F., Pivonello R., Ambrogio A.G. et al. The dexamethasonesup ressed corticotropinreleasing hormone stimulation test and the desmopressin test to distinguish Cushing’s
syndrome from pseudoCushing’s states. Clin. Endocr. (Oxf.)
2007; 66: 251–257.
13. Ross E.J., Linch D.C. Cushing’s syndrome—killing disease:
discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; 2: 646–649.
14. Erbil Y., Ademoglu E., Ozbey N. et al. Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome
before and after surgery. Wld J. Surg. 2006; 30: 1665–1671.
15. Chiodini I., Tauchmanova L., Torlontano M. et al. Bone
involvement in eugonadal male patients with adrenal incidentaloma and subclinical hypercortisolism. J. Clin. Endocr.
Metab. 2002; 87: 5491–5494.
16. Rossi R., Tauchmanova L., Luciano A. et al. Subclinical
Cushing’s syndrome in patients with adrenal incidentaloma:
clinical and biochemical features. J. Clin. Endocr. Metab.
2000; 85: 1440–1448.
17. Tauchmanova L., Rossi R., Biondi B. et al. Patients with subclinical Cushing’s syndrome due to adrenal adenoma have
increased cardiovascular risk. J. Clin. Endocr. Metab. 2002;
87: 4872–4878.
18. Barzon L., Fallo F., Sonino N., Boscaro M. Development of
overt Cushing’s syndrome in patients with adrenal incidentaloma. Eur. J. Endocr. 2002; 146: 61–66.
19. Libe R., Dall’Asta C., Barbetta L. et al. Longterm follow-up
study of patients with adrenal incidentalomas. Eur. J. Endocr.
2002; 147: 489–494.
20. Samaras K., Pett S., Gowers A. et al. Iatrogenic Cushing’s
syndrome with osteoporosis and secondary adrenal failure in
human immunodeficiency virus-infected patients receiving
inhaled corticosteroids and ritonavir-boosted protease
inhibitors: six cases. J. Clin. Endocr. Metab. 2005; 90:
4394–4398.
21. Mann M., Koller E., Murgo A. et al. Glucocorticoidlike activity
of megestrol. A summary of Food and Drug Administration
experience and a review of the literature. Arch. Intern. Med.
1997; 157:1651–1656.
22. Nieman L.K., Biller B.M.K., Findling J.W. et al. The diagnosis
of Cushing’s syndrome:an endocrine society clinical practice
guideline. J. Clin. Endocr. Metab. 2008; 93 (5): 1526–1540.
23. Newell-Price J., Trainer P., Besser M., Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and
pseudo-Cushing's states. Endocr. Rev. 1998; 19: 647–672.
24. Crapo L. Cushing’s syndrome: a review of diagnostic tests.
Metabolism 1979; 28: 955–977.
25. Cronin C., Igoe D., Duffy M.J. et al. The overnight dexamethasone test is a worthwhile screening procedure. Clin.
Endocrinol. (Oxf.) 1990; 33: 27–33.
26. Invitti C., Pecori Giraldi F., de Martin M., Cavagnini F.
Diagnosis and management of Cushing’s syndrome: results
of an Italian multicentre study. Study Group of the Italian
Society of Endocrinology on the Pathophysiology of the
Hypothalamic-Pituitary-Adrenal Axis. J. Clin. Endocr. Metab.
1999; 84: 440–448.
27. Findling J.W., Raff H., Aron D.C. The low-dose dexamethasone suppression test: a reevaluation in patients with
Cushing’s syndrome. J. Clin. Endocr. Metab. 2004; 89:
1222–1226.
28. Gorges R., Knappe G., Gerl H. et al. Diagnosis of Cushing’s
syndrome: re-evaluation of midnight plasma cortisol vs urinary free cortisol and low-dose dexamethasone suppression
test in a large patient group. J. Endocr. Invest. 1999; 22:
241–249.
29. Wood P.J., Barth J.H., Freedman D.B. et al. Evidence for the low
dose dexamethasone suppression test to screen for Cushing’s
syndrome-recommendations or a protocol for biochemistry
laboratories. Ann. Clin. Biochem. 1997; 34 (Pt 3): 222–229.
30. Yanovski J.A., Cutler G.B.Jr., Chrousos G.P., Nieman L.K.
Corticotropin-releasing hormone stimulation following lowdose dexamethasone administration. A new test to distinguish Cushing’s syndrome from pseudo-Cushing’s states.
J.A.M.A. 1993; 269: 2232–2238.
31. Eisenhofer G. et al. Pheochromocytoma: rediscovery as a
catecholamine-metabolizing tumor. Endocr. Pathol. 2003; 14:
193–212.
32. Gardet V. et al. Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. J.
Hypertens. 2001; 19: 1029–1035;
33. Gerlo E., Sevens C. Urinary and plasma catecholamines and
urinary catecholamine metabolites in pheochromocytoma:
diagnostic value in 19 cases. Clin. Chem. 1994; 40: 250–256.
34. Guller U. et al. Detecting pheochromocytoma: defining the
most sensitive test. Ann. Surg. 2006. 243: 102–107.
35. Lenders J.W. et al. Biochemical diagnosis of pheochromocytoma: which test is best? J.A.M.A. 2002. 287: 1427–1434.
36. Raber W. et al. Diagnostic efficacy of unconjugated plasma
metanephrines for the detection of pheochromocytoma.
Arch. Intern. Med. 2000; 160: 2957–2963.
37. Sawka A.M. et al. A comparison of biochemical tests for
pheochromocytoma: measurement of fractionated plasma
metanephrines compared with the combination of 24-hour
urinary metanephrines and catecholamines. J. Clin. Endocr.
Metab. 2003; 88: 553–558.
38. Unger N. et al. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patientwith adrenal mass. Eur. J. Endocr. 2006; 154: 409–417.
39. Кузнецов Н.С., Бельцевич Д.Г., Гончаров Н.П. и др. Повышение уровня метилированных производных катехоламинов – патогномоничный лабораторный признак феохромоцитомы. Пробл. эндокринол. 2007; 1: 33–36.
40. Erlic Z., Neumann H. Familial pheochromocytoma. Hormones
2009; 1: 29–38.
41. Young W.F.Jr. Primary aldosteronism: management issues.
Ann. N. Y. Acad. Sci. 2002; 970: 61–76.
42. Hiramatsu K., Yamada T., Yukimura Y. et al. A screening test
to identify aldosteroneproducing adenoma by measuring
plasma renin activity. Results in hypertensive patients. Arch.
Int. Med. 1981;141:1589–1593.
43. Funder J.W. et al. Guidelines for Management of Patients with
Primary Aldosteronism. J. Clin. Endocr. Metab. 2008. First
published ahead of print June 13.
44. McKenna T.J., Sequeira S.J., Heffernan A. et al. Diagnosis
under random conditions of all disorders of the reninangiotensin-aldosterone axis, including primary hyperaldosteronism. J. Clin. Endocr. Metab. 1991; 73: 952–957.
45. Stowasser M., Gordon R.D., Gunasekera T.G. et al. High rate
of detection of primary aldosteronism, including surgically
treatable forms, after 'non-selective' screening of hypertensive patients. J. Hypertens. 2003; 21: 2149–2157.
46. Montori V.M., Schwartz G.L., Chapman A.B. et al. Validity of
the aldosteronerenin ratio used to screen for primary aldosteronism. Mayo Clin. Proc. 2001. 76: 877–882.
47. Hussain HK, Korobkin M. MR imaging of the adrenal glands.
Magn. Reson. Imaging Clin. N. Am. 2004; 12: 515–544.
48. Kempers M., Lenders J. et al. Diagnostic Procedures to
Differentiate Unilateral From Bilateral Adrenal Abnormality in
Primary Aldosteronism. Ann. Intern. Med. 2009; 151:
329–337.
49. Mansmann G., Lau J., Balk E. et al. The clinically inapparent
adrenal mass: update in diagnosis and management. Endocr.
Rev. 2004; 25: 309–340.
50. Young W.F.Jr. The Incidentally Discovered Adrenal Mass.
N. Engl. J. Med. 2007; 356: 601–610.

Keywords: